The Pharmacological Management of Constipation in Patients With Parkinson’S Disease: A Much-Needed Relief Publisher Pubmed



Mozaffari S^{1, 2} ; Nikfar S^{2, 3} ; Daniali M^{1, 4} ; Abdollahi M^{1, 4}
Source: Expert Opinion on Pharmacotherapy Published:2020

Abstract

Introduction: Constipation is common in patients with Parkinson’s disease (PD). Due to the considerable negative outcomes of constipation, significant efforts have been made to prevent and manage chronic constipation in these patients. Areas covered: Herein, the authors review some of the known pathophysiological causes for slow gastrointestinal (GI) transit in PD patients and the different pharmacological options. All relevant clinical and experimental data found through online databases were included. Bulking agents, osmotic and stimulant laxatives, chloride channel activators, ghrelin agonists, 5-HT4 receptor agonists, and probiotics are some of the proposed medicinal agents. of the authors further review the evidence on alpha-synuclein and botulinum neurotoxin in these patients. It should be noted, however, that some of these interventions are required to be further validated. Expert opinion: Reduction of GI transit and dysfunction of the anorectum is obvious in PD, affecting the incidence of constipation and thus, quality of life (QOL). Furthermore, due to an inadequate and delayed absorption of oral anti PD medications, dose adjustments and changes in the route of administration are recommended. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.